The endothelin receptor antagonist bosentan [`Tracleer'; Actelion] has been approved in Canada

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1318, 2001-01, pp. : 22-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bosentan: a dual endothelin receptor antagonist

By Roux Sébastien Rubin Lewis J

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 7, 2002-07 ,pp. : 991-1002

Informa Healthcare

Access to resources Recommend Favorite

Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist

By Jasper Dingemanse Paul L.M. van Giersbergen

Clinical Pharmacokinetics, Vol. 43, Iss. 15, 2004-01 ,pp. : 1089-1115

Adis International

Access to resources Recommend Favorite

Estradiol/norethisterone has been approved by Health Canada

Inpharma, Vol. 1, Iss. 1644, 2008-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor

By van Giersbergen P.L.M. Gnerre C. Treiber A. Dingemanse J. Meyer U.A.

European Journal of Pharmacology, Vol. 450, Iss. 2, 2002-08 ,pp. : 115-121

Elsevier

Access to resources Recommend Favorite

Verteporfin [`Visudyne'; Novartis, QLT] has been approved in Canada

Inpharma, Vol. 1, Iss. 1299, 2001-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite